Transcriptional Signatures of Synaptic Vesicle Genes Define Myotonic Dystrophy Type I Neurodegeneration

Overview

Journal Neuropathol Appl Neurobiol

Specialty Neurology

Date 2021 May 6

PMID 33955002

Citations 8

Authors

Antonio Jimenez-Marin

Ibai Diez

Garazi Labayru

Andone Sistiaga

Maria C Caballero

Pol Andres-Benito

Jorge Sepulcre

Isidro Ferrer

Adolfo Lopez de Munain

Jesus M Cortes

Affiliations

Soon will be listed here.

Abstract

Aim: To delineate the neurogenetic profiles of brain degeneration patterns in myotonic dystrophy type I (DM1).

Methods: In two cohorts of DM1 patients, brain maps of volume loss (VL) and neuropsychological deficits (NDs) were intersected to large-scale transcriptome maps provided by the Allen Human Brain Atlas (AHBA). For validation, neuropathological and RNA analyses were performed in a small series of DM1 brain samples.

Results: Twofold: (1) From a list of preselected hypothesis-driven genes, confirmatory analyses found that three genes play a major role in brain degeneration: dystrophin (DMD), alpha-synuclein (SNCA) and the microtubule-associated protein tau (MAPT). Neuropathological analyses confirmed a highly heterogeneous Tau-pathology in DM1, different to the one in Alzheimer's disease. (2) Exploratory analyses revealed gene clusters enriched for key biological processes in the central nervous system, such as synaptic vesicle recycling, localization, endocytosis and exocytosis, and the serotonin and dopamine neurotransmitter pathways. RNA analyses confirmed synaptic vesicle dysfunction.

Conclusions: The combination of large-scale transcriptome interactions with brain imaging and cognitive function sheds light on the neurobiological mechanisms of brain degeneration in DM1 that might help define future therapeutic strategies and research into this condition.

Citing Articles

Open datasets and code for multi-scale relations on structure, function and neuro-genetics in the human brain.

Jimenez-Marin A, Diez I, Erramuzpe A, Stramaglia S, Bonifazi P, Cortes J Sci Data. 2024; 11(1):256.

PMID: 38424112 PMC: 10904384. DOI: 10.1038/s41597-024-03060-2.

Mbnl2 loss alters novel context processing and impairs object recognition memory.

Khandelwal A, Cushman J, Choi J, Zhuravka I, Rajbhandari A, Valiulahi P iScience. 2023; 26(5):106732.

PMID: 37216102 PMC: 10193234. DOI: 10.1016/j.isci.2023.106732.

Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow-up study.

Garmendia J, Labayru G, Zulaica M, Villanua J, de Munain A, Sistiaga A Eur J Neurol. 2022; 30(1):215-223.

PMID: 36256504 PMC: 10092190. DOI: 10.1111/ene.15604.

Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1.

Nakamori M, Shimizu H, Ogawa K, Hasuike Y, Nakajima T, Sakurai H Brain Commun. 2022; 4(3):fcac154.

PMID: 35770133 PMC: 9218787. DOI: 10.1093/braincomms/fcac154.

Calpain-2 Mediates MBNL2 Degradation and a Developmental RNA Processing Program in Neurodegeneration.

Wang L, Lin C, Lin Y, Buee L, Sergeant N, Blum D J Neurosci. 2022; 42(25):5102-5114.

PMID: 35606145 PMC: 9233439. DOI: 10.1523/JNEUROSCI.2006-21.2022.

References

Smith S, Nichols T . Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2008; 44(1):83-98. DOI: 10.1016/j.neuroimage.2008.03.061. View

Modoni A, Silvestri G, Pomponi M, Mangiola F, Tonali P, Marra C . Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol. 2004; 61(12):1943-7. DOI: 10.1001/archneur.61.12.1943. View

Dhaenens C, Tran H, Frandemiche M, Carpentier C, Schraen-Maschke S, Sistiaga A . Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochim Biophys Acta. 2011; 1812(7):732-42. DOI: 10.1016/j.bbadis.2011.03.010. View

Burt J, Helmer M, Shinn M, Anticevic A, Murray J . Generative modeling of brain maps with spatial autocorrelation. Neuroimage. 2020; 220:117038. DOI: 10.1016/j.neuroimage.2020.117038. View

Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H . Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992; 68(4):799-808. DOI: 10.1016/0092-8674(92)90154-5. View

Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V . Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics. 2017; 18(1):142. PMC: 5333408. DOI: 10.1186/s12859-017-1559-2. View

Serra L, Petrucci A, Spano B, Torso M, Olivito G, Lispi L . How genetics affects the brain to produce higher-level dysfunctions in myotonic dystrophy type 1. Funct Neurol. 2015; 30(1):21-31. PMC: 4520669. View

Labayru G, Jimenez-Marin A, Fernandez E, Villanua J, Zulaica M, Cortes J . Neurodegeneration trajectory in pediatric and adult/late DM1: A follow-up MRI study across a decade. Ann Clin Transl Neurol. 2020; 7(10):1802-1815. PMC: 7545612. DOI: 10.1002/acn3.51163. View

Hernandez-Hernandez O, Guiraud-Dogan C, Sicot G, Huguet A, Luilier S, Steidl E . Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain. 2013; 136(Pt 3):957-70. PMC: 3580270. DOI: 10.1093/brain/aws367. View

10.

Fukuda H, Horiguchi J, Ono C, Ohshita T, Takaba J, Ito K . Diffusion tensor imaging of cerebral white matter in patients with myotonic dystrophy. Acta Radiol. 2005; 46(1):104-9. DOI: 10.1080/02841850510015974. View

11.

Vermersch P, Sergeant N, Ruchoux M, Hofmann-Radvanyi H, WATTEZ A, Petit H . Specific tau variants in the brains of patients with myotonic dystrophy. Neurology. 1996; 47(3):711-7. DOI: 10.1212/wnl.47.3.711. View

12.

Burt J, Demirtas M, Eckner W, Navejar N, Ji J, Martin W . Hierarchy of transcriptomic specialization across human cortex captured by structural neuroimaging topography. Nat Neurosci. 2018; 21(9):1251-1259. PMC: 6119093. DOI: 10.1038/s41593-018-0195-0. View

13.

Sepulcre J, Grothe M, dOleire Uquillas F, Ortiz-Teran L, Diez I, Yang H . Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med. 2018; 24(12):1910-1918. PMC: 6518398. DOI: 10.1038/s41591-018-0206-4. View

14.

Caso F, Agosta F, Peric S, Rakocevic-Stojanovic V, Copetti M, Kostic V . Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage. PLoS One. 2014; 9(8):e104697. PMC: 4130603. DOI: 10.1371/journal.pone.0104697. View

15.

Lee J, Cooper T . Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009; 37(Pt 6):1281-6. PMC: 3873089. DOI: 10.1042/BST0371281. View

16.

de Las Heras J, Diez I, Jimenez-Marin A, Cabrera A, Ramos-Usuga D, Diaz-Fernandez M . Brain Circuit Alterations and Cognitive Disability in Late-Onset Cobalamin D Disorder. J Clin Med. 2020; 9(4). PMC: 7231091. DOI: 10.3390/jcm9040990. View

17.

Winblad S, Lindberg C, Hansen S . Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1). Behav Brain Funct. 2006; 2:16. PMC: 1475858. DOI: 10.1186/1744-9081-2-16. View

18.

Minnerop M, Weber B, Schoene-Bake J, Roeske S, Mirbach S, Anspach C . The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain. 2011; 134(Pt 12):3530-46. PMC: 3235566. DOI: 10.1093/brain/awr299. View

19.

Weber Y, Roebling R, Kassubek J, Hoffmann S, Rosenbohm A, Wolf M . Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology. 2010; 74(14):1108-17. DOI: 10.1212/WNL.0b013e3181d8c35f. View

20.

Sergeant N, Sablonniere B, Schraen-Maschke S, Ghestem A, Maurage C, WATTEZ A . Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet. 2001; 10(19):2143-55. DOI: 10.1093/hmg/10.19.2143. View